Most anticancer drugs fail to impact patient survival since they fail to cross the blood-brain tumor barrier (BTB) at therapeutic levels. For example, Temozolomide (TMZ) exhibits some antitumor activity against brain tumors, so does Trastuzumab (Herceptin, Her-2 inhibitor), which might be effective against Her2 neu overexpressing gliomas. Nevertheless, intact BTB and active efflux system may prevent their entry to brain tumors. Previously we have shown that potassium channel agonists increased carboplatin and Her-2 neu antibody delivery in animal glioma models. here, we studied whether potassium channel agonist increase TMZ and herceptin delivery across the BTB to elicit antitumor activity and increase survival in nude mice with human glial tumor. The KCa channel activity and expression was also evaluated in human glioma tissues. We administered NS-1619, calcium-dependent potassium (KCa) channel agonist, with [14C]-TMZ, and quantified TMZ delivery. The results clearly demonstrate that when given systemically both TMZ and Herceptin do not cross the BTB in significant amounts, however, NS-1619 co-infusion with [ 14C]-TMZ and herceptin resulted in enhanced drug delivery to brain-tumor cells. The combination treatment of TMZ and herceptin also showed improved antitumor effect which was more prominent than that of either treatment alone in increasing the survival in mice with brain tumor, when co-infused with KCa channel agonists. In conclusion, KCa channel agonists may benefit brain tumor patients by increasing anti-neoplastic agent's delivery to brain tumors. A clinical outcome of this research is the discovery of a novel drug delivery system that circumvents the BBB/BTB to benefit brain tumor patients.
|Number of pages||10|
|Journal||Cancer Biology and Therapy|
|State||Published - 15 Oct 2009|
- Blood-brain barrier
- Drug delivery
- K channels